Prilosec OTC, Nexium Launches Fed “Shark Fin” Monopoly Plan, Suit Claims
This article was originally published in The Tan Sheet
Executive Summary
Elements of the Prilosec OTC launch, ranging from the drug's 14-day term of use to supply shortages during its time on the market, were part of a plan by AstraZeneca to interfere with generic competition for its prescription proton pump inhibitors, retailers allege in a lawsuit against the U.K. drug maker
You may also be interested in...
Follow-On Brand Drugs Could Draw FTC Anticompetitive Scrutiny
The introduction of certain follow-on brand drugs as the original product nears patent expiration could raise anticompetitive concerns at the Federal Trade Commission, according to FTC Commissioner Pamela Harbour
Prilosec OTC Shortages Due To Inaccurate Projections, Global Supply Chain
Procter & Gamble is building up enough Prilosec OTC inventory to allow retailers to re-launch the product
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.